Bliss Gvs Pharma Limited (IN:BLISSGVS)
:BLISSGVS
Want to see IN:BLISSGVS full AI Analyst Report?
BLISSGVS Stock Chart & Stats
₹144.75
-₹6.85(-3.92%)
At close: 4:00 PM EST
₹144.75
-₹6.85(-3.92%)
Day’s Range― - ―
52-Week Range₹118.35 - ₹493.70
Previous CloseN/A
Volume571.01K
Average Volume (3M)104.36K
Market Cap
₹51.48B
Enterprise Value₹50.10B
Total Cash (Recent Filing)₹2.01B
Total Debt (Recent Filing)₹524.91M
Price to Earnings (P/E)40.7
Beta1.26
Next Earnings
Aug 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.28%
Share Statistics
EPS (TTM)10.40
Shares Outstanding105,788,970
10 Day Avg. Volume77,644
30 Day Avg. Volume104,358
Financial Highlights & Ratios
PEG Ratio0.36
Price to Book (P/B)2.03
Price to Sales (P/S)2.61
P/FCF Ratio29.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetLow and declining debt alongside rising equity and assets provides durable financial flexibility. For a specialty/generic pharma, this supports funding regulatory filings, capacity expansion, and working capital for exports without heavy reliance on external financing, reducing solvency risk over multiple quarters.
Improved Cash GenerationA rebound to strong operating and free cash flow improves the firm's ability to self-fund capex, R&D, and contract-manufacturing investments. Sustainable cash generation reduces refinancing needs and enables steady investment in manufacturing capacity and commercial reach over the coming 2–6 months and beyond.
Consistent Revenue GrowthSteady mid-to-high single-digit revenue growth reflects stable demand for finished formulations across domestic and export channels. Persistent top-line growth supports scale economics in manufacturing and distribution, helping margins and enabling strategic reinvestment into core therapy areas like women’s health.
Bears Say
Margin VolatilityHistoric margin swings and a very weak profit year highlight unstable earnings power. For a generics/formulations player, pricing pressure, product mix shifts or one-off items can quickly erode profitability, making medium-term earnings forecasts and capital allocation decisions more uncertain.
Choppy Cash ConversionLarge swings in free cash flow and past negative FCF indicate unpredictable working-capital needs or timing of receipts/payments. This reduces visibility on sustainable free cash generation and can constrain investments or require temporary external funding during adverse cycles.
Operating Profitability ClarityAn atypical EBITDA vs EBIT relationship suggests non-standard expense or accounting items affecting operating results. That obscures true recurring operating margins, complicates forecasting and increases risk that reported profits may not reflect sustainable core business performance over the medium term.
Bliss Gvs Pharma Limited News
BLISSGVS FAQ
What was Bliss Gvs Pharma Limited’s price range in the past 12 months?
Bliss Gvs Pharma Limited lowest stock price was ₹118.35 and its highest was ₹493.70 in the past 12 months.
What is Bliss Gvs Pharma Limited’s market cap?
Bliss Gvs Pharma Limited’s market cap is ₹51.48B.
When is Bliss Gvs Pharma Limited’s upcoming earnings report date?
Bliss Gvs Pharma Limited’s upcoming earnings report date is Aug 04, 2026 which is in 43 days.
How were Bliss Gvs Pharma Limited’s earnings last quarter?
Currently, no data Available
Is Bliss Gvs Pharma Limited overvalued?
According to Wall Street analysts Bliss Gvs Pharma Limited’s price is currently Overvalued.
Does Bliss Gvs Pharma Limited pay dividends?
Bliss Gvs Pharma Limited pays a Annually dividend of ₹0.5 which represents an annual dividend yield of 0.28%. See more information on Bliss Gvs Pharma Limited dividends here
What is Bliss Gvs Pharma Limited’s EPS estimate?
Bliss Gvs Pharma Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bliss Gvs Pharma Limited have?
Bliss Gvs Pharma Limited has 105,788,970 shares outstanding.
What happened to Bliss Gvs Pharma Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Bliss Gvs Pharma Limited?
Currently, no hedge funds are holding shares in IN:BLISSGVS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bliss Gvs Pharma Limited
Established in 1984 and headquartered in Mumbai, India, Bliss GVS Pharma Limited specializes in the development, manufacturing, and distribution of a comprehensive array of pharmaceutical products. The company's pharmaceutical portfolio includes an extensive range of dosage forms, such as oral solids (tablets, capsules), various liquid and injectable preparations, topical applications (creams, gels), and advanced drug delivery systems like transdermal patches. Beyond conventional medicines, Bliss GVS also offers a diverse selection of other healthcare and personal care items, including balms, lotions, shampoos, and over-the-counter remedies. Their therapeutic focus is equally broad, encompassing solutions for anti-infectives, pain management, gastrointestinal issues, anti-malarials, dermatological conditions, nutritional support, and a wide variety of other wellness and hygiene products, including medicated and cosmetic soaps. The company actively engages in international exports, extending its market presence beyond India.
Technical Analysis
Bajaj Healthcare Ltd
―
Hester Biosciences Limited
―
Jagsonpal Pharmaceuticals Ltd.
―
Syncom Formulation (India) Ltd.
―
Windlas Biotech Ltd.
―